A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate

Trial Profile

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs ABT 122 (Primary) ; Adalimumab
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 13 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 09 Jul 2016 The trial is completed in Hungary (End date:2016-07-01) as per European Clinical Trials Database record.
    • 12 May 2016 The trial is completed in Germany and Czech republic as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top